Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparison of Cystic Fibrosis Healthcare Providers’ Observations in Europe and the United States
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has been associated with improvements in physical health and well-being. However, there are growing concerns about side-effects related to sleep, cognition and new or worsening mental health in a subs
Authors
- Marieke Verkleij (ORCID: https://orcid.org/0000-0003-2787-5440)
- Alexandra L. Quittner (ORCID: https://orcid.org/0000-0002-4139-6983)
- E. Landau (ORCID: https://orcid.org/0000-0001-8002-9708)
- Sonia Graziano (ORCID: https://orcid.org/0000-0002-7478-8414)
- Anna M. Georgiopoulos (ORCID: https://orcid.org/0000-0002-0924-4031)
- Beth A. Smith (ORCID: https://orcid.org/0000-0003-2531-5394)
- Christina J. Bathgate (ORCID: https://orcid.org/0000-0002-7120-2799)
- U. Borawska - Kowalczyk
- Horst Mitmansgrubert
Institutions
- American Academy of Child and Adolescent Psychiatry (US)
- National Jewish Health (US)
- Emma Kinderziekenhuis (NL)
- Assaf Harofeh Medical Center (IL)
- Bambino Gesù Children's Hospital (IT)
- Instytut Matki i Dziecka (PL)
- Klinik und Poliklinik für Psychiatrie und Psychotherapie (DE)
- Amsterdam University Medical Centers (NL)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University at Buffalo, State University of New York (US)
- University of Colorado Denver (US)
Publication Details
- Published
- 2025-08-26
- DOI
- https://doi.org/10.22541/au.175619006.65159367/v1
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cystic Fibrosis Foundation
- Ministero della Salute